More News

06 Sep 2022 PhoreMost enters multi-project drug target discovery collaboration with Roche
01 Sep 2022 Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
23 Aug 2022 NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)
17 Aug 2022 Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery
16 Aug 2022 Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
11 Aug 2022 ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
11 Aug 2022 GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
10 Aug 2022 Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
08 Aug 2022 Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
05 Aug 2022 Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China
05 Aug 2022 Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
05 Aug 2022 Gilead Sciences to acquire MiroBio
05 Aug 2022 Amgen to acquire Chemocentryx for $4 billion in cash
04 Aug 2022 Radiopharm enters into strategic collaboration with Lantheus and assumes PD-L1 licensing agreement from Nanomab
03 Aug 2022 Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
29 Jul 2022 Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease
29 Jul 2022 Novartis and UC Berkeley Extend Alliance to Tackle 'Undruggable' Disease Targets and Discover New Therapeutic Modalities
25 Jul 2022 Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform
21 Jul 2022 Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
18 Jul 2022 Enterome signs major strategic R&D collaboration with Nestlé Health Science to develop and commercialize new AllerMimics™ and EndoMimics™ immunotherapies for food allergies and inflammatory bowel disease
13 Jul 2022 Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer
13 Jul 2022 Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
12 Jul 2022 LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate
12 Jul 2022 Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
07 Jul 2022 Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top